[
    {
        "question_id": "1_B_9432",
        "new_question_id": "5747",
        "question_type": "0",
        "category": "9",
        "concept_id_link": "0",
        "notes_id_link": "1_1914",
        "theme": "",
        "instruction": "",
        "options": [
            "",
            "Extradural haemorrhage",
            "Subdural haemorrhage",
            "Subarachnoid haemorrhage",
            "Intracerebral haemorrhage",
            "Diffuse axonal injury",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "A 23-year-old man was driving a car at high speed whilst intoxicated, he was wearing a seat belt. The car collides with a brick wall at around 140km/h. When he arrives in the emergency department he is comatose. His CT scan appears to be normal. He remains in a persistent vegetative state. What is the most likely underlying cause?",
            "",
            ""
        ],
        "answers": [
            "5",
            "",
            ""
        ],
        "notes": [
            "Diffuse axonal injury occurs when the head is rapidly accelerated or decelerated. There are 2 components:<br /><br />1. Multiple haemorrhages<br />2. Diffuse axonal damage in the white matter<br /><br />Up to 2/3 occur at the junction of grey/white matter due to the different densities of the tissue.  The changes are mainly histological and axonal damage is secondary to biochemical cascades.  Often there are no signs of a fracture or contusion.",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "A 23-year-old man was driving a car at high speed whilst intoxicated, he was wearing a seat belt. The car collides with a brick wall at around 140km/h. When he arrives in the emergency department he is comatose. His CT scan appears to be normal. He remains in a persistent vegetative state. What is the most likely underlying cause?",
        "correct_answer": "5",
        "question_notes": "Diffuse axonal injury occurs when the head is rapidly accelerated or decelerated. There are 2 components:<br /><br />1. Multiple haemorrhages<br />2. Diffuse axonal damage in the white matter<br /><br />Up to 2/3 occur at the junction of grey/white matter due to the different densities of the tissue.  The changes are mainly histological and axonal damage is secondary to biochemical cascades.  Often there are no signs of a fracture or contusion.",
        "answer_order": "5",
        "answer": "5",
        "title": "Head injury: types of traumatic brain injury",
        "body": "Basics<br /><ul><li>primary brain injury may be focal (contusion/haematoma) or diffuse (diffuse axonal injury)</li><li>diffuse axonal injury occurs as a result of mechanical shearing following deceleration, causing disruption and tearing of axons</li><li>intra-cranial haematomas can be extradural, subdural or intracerebral, while contusions may occur adjacent to (coup) or contralateral (contre-coup) to the side of impact</li><li>secondary brain injury occurs when cerebral oedema, ischaemia, infection, tonsillar or tentorial herniation exacerbates the original injury. The normal cerebral auto regulatory processes are disrupted following trauma rendering the brain more susceptible to blood flow changes and hypoxia</li><li>the Cushings reflex (hypertension and bradycardia) often occurs late and is usually a pre terminal event</li></ul><br /><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid1\" ><thead><tr><th><b>Type of injury</b></th><th><b>Notes</b></th></tr></thead><tbody><tr><td><b>Extradural (epidural) haematoma</b></td><td>Bleeding into the space between the dura mater and the skull. Often results from acceleration-deceleration trauma or a blow to the side of the head. The majority of epidural haematomas occur in the temporal region where skull fractures cause a rupture of the middle meningeal artery.<br /><br />Features<br /><ul><li>features of raised intracranial pressure</li><li>some patients may exhibit a <span class=\"concept\" data-cid=\"8294\">lucid interval</span></td></tr><tr><td></li></ul><b>Subdural haematoma</b></td><td>Bleeding into the outermost meningeal layer. Most commonly occur around the frontal and parietal lobes.<br /><br />Risk factors include <span class=\"concept\" data-cid=\"8295\">old age, alcoholism</span> and anticoagulation.<br /><br />Slower onset of symptoms than a epidural haematoma. There may be <span class=\"concept\" data-cid=\"485\">fluctuating confusion/consciousness</span></td></tr><tr><td><b>Subarachnoid haemorrhage</b></td><td>Classically causes a <span class=\"concept\" data-cid=\"8296\">sudden occipital headache</span>. Usually occurs spontaneously in the context of a ruptured cerebral aneurysm but may be seen in association with other injuries when a patient has sustained a traumatic brain injury</td></tr><tr><td><b>Intracerebral haematoma</b></td><td>An intracerebral (or intraparenchymal) haemorrhage is a collection of blood within the substance of the brain. <br /><br />Causes / risk factors include: hypertension, vascular lesion (e.g. aneurysm or arteriovenous malformation), cerebral amyloid angiopathy, trauma, brain tumour or infarct (particularly in stroke patients undergoing thrombolysis). <br /><br />Patients will present similarly to an ischaemic stroke (which is why it is crucial to obtain a CT in head in all stroke patients prior to thrombolysis) or with a decrease in consciousness. <br /><br />CT imaging will show a hyperdensity (bright lesion) within the substance of the brain. <br /><br />Treatment is often conservative under the care of stroke physicians, but large clots in patients with impaired consciousness may warrant surgical evacuation.</td></tr></tbody></table></div><br /><h5 class='notes-heading'>Image gallery</h5><br />Extradural (epidural) haematoma:<br /><br /><div class=\"container\"><div class=\"row\"><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb033b.jpg\" data-fancybox=\"gallery\" data-caption=\"Extradural (epidural) haematoma - Image used on license from Radiopaedia\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb033.jpg\" alt=\"\" /></a></div><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb032b.jpg\" data-fancybox=\"gallery\" data-caption=\"Extradural (epidural) haematoma -  Image used on license from Radiopaedia\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb032.jpg\" alt=\"\" /></a></div><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb034b.jpg\" data-fancybox=\"gallery\" data-caption=\"Extradural (epidural) haematoma -  Image used on license from Radiopaedia\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb034.jpg\" alt=\"\" /></a></div><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb989b.jpg\" data-fancybox=\"gallery\" data-caption=\"Non-contrast CT image of a traumatic extradural hematoma in the left frontal-temporal region.\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb989.jpg\" alt=\"\" /></a></div></div></div><br />Subdural haematoma:<br /><br /><div class=\"container\"><div class=\"row\"><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb946b.jpg\" data-fancybox=\"gallery\" data-caption=\"CT (non-contrast) showing subdural haematoma in an elderly woman. Mass effect and midline shift -  Image used on license from Radiopaedia\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb946.jpg\" alt=\"\" /></a></div><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb031b.jpg\" data-fancybox=\"gallery\" data-caption=\"Subdural haematoma -  Image used on license from Radiopaedia\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb031.jpg\" alt=\"\" /></a></div><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb002b.jpg\" data-fancybox=\"gallery\" data-caption=\"Subdural haematoma -  Image used on license from Radiopaedia\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb002.jpg\" alt=\"\" /></a></div><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb983b.jpg\" data-fancybox=\"gallery\" data-caption=\"There is a large crescent-shaped area of high density over the right side of the brain, extending from the top (right medial convexity) to the bottom (right temporal lobe). This has caused a midline shift of brain structures, along with subfalcine herniation (where brain tissue is pushed under the falx cerebri).\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb983.jpg\" alt=\"\" /></a></div></div><div class=\"row\"><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb985b.jpg\" data-fancybox=\"gallery\" data-caption=\"Subdural haematoma with significant midline shift\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb985.jpg\" alt=\"\" /></a></div><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb986b.jpg\" data-fancybox=\"gallery\" data-caption=\"Subdural haematoma\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb986.jpg\" alt=\"\" /></a></div></div></div><br />Subarachnoid haemorrhage:<br /><br /><div class=\"container\"><div class=\"row\"><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb035b.jpg\" data-fancybox=\"gallery\" data-caption=\"Subarachnoid haemorrhage - Image used on license from Radiopaedia\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb035.jpg\" alt=\"\" /></a></div><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb179b.jpg\" data-fancybox=\"gallery\" data-caption=\"Subarachnoid haemorrhage - Image used on license from Radiopaedia\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb179.jpg\" alt=\"\" /></a></div><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb988b.jpg\" data-fancybox=\"gallery\" data-caption=\"CT showing a subarachnoid haemorrhage as a white area in the centre (marked by the arrow) and stretching into the sulci to either side\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/xrb988.jpg\" alt=\"\" /></a></div></div></div>",
        "notes_hash": "f5da6e37a541dec359bc01152644ed9e",
        "knowledge_graph_node_id_link": 11199,
        "concept": "",
        "concept_percentile": 0,
        "concept_colour": "",
        "number_attempts": "6241",
        "up_votes": "30",
        "down_votes": "8",
        "column_array": [
            0,
            "366",
            "314",
            "311",
            "501",
            "4749",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "<table style='width:100%'><tr><td>NICE</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_217\" data-linkid=\"217\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_217\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">19</span><button type=\"button\" style=\"\" id=\"link_dislike_217\" data-linkid=\"217\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_217\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">3</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https://www.nice.org.uk/guidance/cg176/chapter/1-Recommendations\">2014 Head injury guidelines</a></td></tr></table>",
        "media": "<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/Kb_wzb7-rvE\" data-description=\"Intracranial Haemorrhage Types\" data-upvotes=\"37\" data-downvotes=\"3\" data-media=\"280\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/Kb_wzb7-rvE/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/Kb_wzb7-rvE\" data-description=\"Intracranial Haemorrhage Types\" data-upvotes=\"37\" data-downvotes=\"3\" data-media=\"280\">Intracranial Haemorrhage Types</a></td></tr><tr><td><span ><small>Armando Hasudungan - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_479\" data-mediaid=\"479\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_479\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">37</span><button type=\"button\" style=\"\" id=\"media_dislike_479\" data-mediaid=\"479\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_479\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">3</span></td></tr><tr><td>&nbsp;</td></tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/hssdJu-81g4\" data-description=\"Traumatic brain injury: pathology review\" data-upvotes=\"8\" data-downvotes=\"1\" data-media=\"1259\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/hssdJu-81g4/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/hssdJu-81g4\" data-description=\"Traumatic brain injury: pathology review\" data-upvotes=\"8\" data-downvotes=\"1\" data-media=\"1259\">Traumatic brain injury: pathology review</a></td></tr><tr><td><span ><small>Osmosis - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_2220\" data-mediaid=\"2220\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_2220\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">8</span><button type=\"button\" style=\"\" id=\"media_dislike_2220\" data-mediaid=\"2220\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_2220\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">1</span></td></tr><tr><td>&nbsp;</td></tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/opnVo7GNZ68\" data-description=\"Intracranial bleeds - Subdural and Extradural haematoma\" data-upvotes=\"1\" data-downvotes=\"1\" data-media=\"318\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/opnVo7GNZ68/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/opnVo7GNZ68\" data-description=\"Intracranial bleeds - Subdural and Extradural haematoma\" data-upvotes=\"1\" data-downvotes=\"1\" data-media=\"318\">Intracranial bleeds - Subdural and Extradural haematoma</a></td></tr><tr><td><span ><small>Soton Brain Hub - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_540\" data-mediaid=\"540\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_540\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">1</span><button type=\"button\" style=\"\" id=\"media_dislike_540\" data-mediaid=\"540\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_540\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">1</span></td></tr></table>",
        "comment_count": 2,
        "concepts_for_notes": {
            "485": {
                "concept_text": "Fluctuating confusion/consciousness? - subdural haematoma",
                "concept_percentile": "77"
            },
            "8294": {
                "concept_text": "Head injury, lucid interval - extradural (epidural) haematoma",
                "concept_percentile": "67"
            },
            "8295": {
                "concept_text": "Elderly, alcoholic, head injury, insidiuous onset symptom - subdural haematoma",
                "concept_percentile": "36"
            },
            "8296": {
                "concept_text": "Sudden occipital headache - subarachnoid haemorrhage",
                "concept_percentile": "4"
            }
        },
        "optimisation_reason": ""
    },
    {
        "question_id": "1_B_1831",
        "new_question_id": "6603",
        "question_type": "0",
        "category": "9",
        "concept_id_link": "0",
        "notes_id_link": "1_2197",
        "theme": "",
        "instruction": "",
        "options": [
            "",
            "Discharge, outpatient CT head within 72 hours",
            "Admit for 12 hours of observation",
            "Discharge with standard head injury advice",
            "CT head scan within 1 hour",
            "Skull x-ray",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "A 24-year-old man is brought to the Emergency Department by his friends. Around 3 hours ago he was allegedly assaulted outside of a nightclub. He was repeatedly punched in the head and has sustained some bruising around his eyes. His friends report that he is 'concussed' and say that he is confused. On examination his GCS is 14 (M6 V4 E4) and he has trouble explaining where he is. There are no focal neurological features. There is no past medical history of note. Tonight he has drunk around three pints of lager. What is the most appropriate management with regards to a possible head injury?",
            "",
            ""
        ],
        "answers": [
            "4",
            "",
            ""
        ],
        "notes": [
            "The correct answer is <b>CT head scan within 1 hour</b>. According to NICE guidelines for head injury assessment, this patient meets the criteria for urgent CT head scanning (within 1 hour) due to having a GCS less than 15 at 2 hours post-injury, and showing signs of confusion/altered mental status. The presence of alcohol consumption does not alter this decision-making process. The patient's periorbital bruising could also suggest a base of skull fracture, which is another indication for urgent CT.<br /><br /><b>Discharge, outpatient CT head within 72 hours</b> is incorrect because this patient requires urgent assessment of potential intracranial injury. Delayed imaging could miss a significant injury requiring immediate intervention, and outpatient scanning is not appropriate for acute head trauma with concerning features.<br /><br /><b>Admit for 12 hours of observation</b> is incorrect as the primary management step. While observation may be required following imaging, the immediate priority is to obtain a CT scan to rule out significant intracranial pathology. Observation alone could miss important findings requiring urgent neurosurgical intervention.<br /><br /><b>Discharge with standard head injury advice</b> is incorrect and potentially dangerous. The patient has concerning features (reduced GCS and confusion) that mandate further investigation before considering discharge. Standard head injury advice alone is appropriate only for minor head injuries without risk factors.<br /><br /><b>Skull x-ray</b> is incorrect as this investigation has largely been superseded by CT scanning in acute head injury assessment. Skull x-rays have poor sensitivity and specificity for intracranial injury and are no longer recommended in the initial assessment of head injuries in adults according to NICE guidelines. They may miss significant intracranial pathology even when there is no skull fracture visible.",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "A 24-year-old man is brought to the Emergency Department by his friends. Around 3 hours ago he was allegedly assaulted outside of a nightclub. He was repeatedly punched in the head and has sustained some bruising around his eyes. His friends report that he is 'concussed' and say that he is confused. On examination his GCS is 14 (M6 V4 E4) and he has trouble explaining where he is. There are no focal neurological features. There is no past medical history of note. Tonight he has drunk around three pints of lager. What is the most appropriate management with regards to a possible head injury?",
        "correct_answer": "4",
        "question_notes": "The correct answer is <b>CT head scan within 1 hour</b>. According to NICE guidelines for head injury assessment, this patient meets the criteria for urgent CT head scanning (within 1 hour) due to having a GCS less than 15 at 2 hours post-injury, and showing signs of confusion/altered mental status. The presence of alcohol consumption does not alter this decision-making process. The patient's periorbital bruising could also suggest a base of skull fracture, which is another indication for urgent CT.<br /><br /><b>Discharge, outpatient CT head within 72 hours</b> is incorrect because this patient requires urgent assessment of potential intracranial injury. Delayed imaging could miss a significant injury requiring immediate intervention, and outpatient scanning is not appropriate for acute head trauma with concerning features.<br /><br /><b>Admit for 12 hours of observation</b> is incorrect as the primary management step. While observation may be required following imaging, the immediate priority is to obtain a CT scan to rule out significant intracranial pathology. Observation alone could miss important findings requiring urgent neurosurgical intervention.<br /><br /><b>Discharge with standard head injury advice</b> is incorrect and potentially dangerous. The patient has concerning features (reduced GCS and confusion) that mandate further investigation before considering discharge. Standard head injury advice alone is appropriate only for minor head injuries without risk factors.<br /><br /><b>Skull x-ray</b> is incorrect as this investigation has largely been superseded by CT scanning in acute head injury assessment. Skull x-rays have poor sensitivity and specificity for intracranial injury and are no longer recommended in the initial assessment of head injuries in adults according to NICE guidelines. They may miss significant intracranial pathology even when there is no skull fracture visible.",
        "answer_order": "4",
        "answer": "4",
        "title": "Head injury: NICE guidance on investigation",
        "body": "NICE has strict and clear guidance regarding which adult patients are safe to discharge and which need further CT head imaging. The latter group are also divided into two further cohorts, those who require an immediate CT head and those requiring CT head within 8 hours of injury:<br /><br />CT head within 1 hour<br /><ul><li>GCS < 13 on initial assessment</li><li>GCS < 15 at 2 hours post-injury</li><li><span class=\"concept\" data-cid=\"11744\">suspected open or depressed skull fracture</span></li><li>any sign of basal skull fracture (haemotympanum, 'panda' eyes, cerebrospinal fluid leakage from the ear or nose, Battle's sign).</li><li>post-traumatic seizure.</li><li>focal neurological deficit.</li><li><span class=\"concept\" data-cid=\"11888\">more than 1 episode of vomiting</span></li></ul><br />CT head scan within 8 hours of the head injury - for adults with any of the following risk factors who have experienced some loss of consciousness or amnesia since the injury:<br /><ul><li>age <span class=\"concept\" data-cid=\"11745\">65 years or older</span></li><li>any history of bleeding or clotting disorders including <span class=\"concept\" data-cid=\"2710\">anticogulants</span></li><li>dangerous mechanism of injury (a pedestrian or cyclist struck by a motor vehicle, an occupant ejected from a motor vehicle or a fall from a height of greater than 1 metre or 5 stairs)</li><li>more than 30 minutes' retrograde amnesia of events immediately before the head injury</li></ul><br />If a patient is on warfarin who have sustained a head injury with no other indications for a CT head scan, perform a CT head scan within 8 hours of the injury.",
        "notes_hash": "585a8162b2c67c4fec665cd148dc128c",
        "knowledge_graph_node_id_link": 11199,
        "concept": "",
        "concept_percentile": 0,
        "concept_colour": "",
        "number_attempts": "6811",
        "up_votes": "53",
        "down_votes": "8",
        "column_array": [
            0,
            "49",
            "696",
            "101",
            "5885",
            "79",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "<table style='width:100%'><tr><td>NICE</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_1194\" data-linkid=\"1194\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_1194\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">17</span><button type=\"button\" style=\"\" id=\"link_dislike_1194\" data-linkid=\"1194\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_1194\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">20</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https://www.nice.org.uk/guidance/cg176/chapter/1-Recommendations\">2014 Head injury guidelines</a></td></tr></table>",
        "media": "",
        "comment_count": 6,
        "concepts_for_notes": {
            "11888": {
                "concept_text": "Following a head injury, more than 1 episode of vomiting is an indication for a CT head within 1 hour",
                "concept_percentile": "85"
            }
        },
        "optimisation_reason": ""
    },
    {
        "question_id": "8816_E_61",
        "new_question_id": "60922",
        "question_type": "1",
        "category": "2",
        "concept_id_link": "0",
        "notes_id_link": "1_2861",
        "theme": "Chronic nasal symptoms",
        "instruction": "For each patients select the SINGLE MOST APPROPRIATE next management step from the list of options",
        "options": [
            "",
            "Oral corticosteroids",
            "Intranasal decongestants",
            "Intranasal corticosteroids",
            "Expectant management",
            "Saline nasal irrigation",
            "Oral antihistamines",
            "Intranasal antihistamines",
            "Refer on the urgent cancer pathway",
            "Refer to ENT",
            "Antibiotics"
        ],
        "num_of_options": 10,
        "questions": [
            "A 40-year-old man presents with persistent nasal discharge and blockage for the last 4 months. He has not had fevers and is otherwise well. When questioned more closely, he states it is almost always the left side only that is blocked. <br /><br />On examination, there is some rhinorrhoea from the left side, but otherwise nothing else of note.",
            "Z 37-xdzq-nkc vnlzm oqdrdmsr vhsg odqrhrsdms mzrzk chrbgzqfd zmc aknbjzfd enq sgd kzrs 6 lnmsgr. Rgd gzr sqhdc hmsqzmzrzk rsdqnhcr, zmc xnt gzud bgdbjdc gdq sdbgmhptd hr bnqqdbs, zmc gzr sqhdc rzkhmd mzrzk cntbghmf. Rgd gzc z rgnqs bntqrd ne zmshahnshbr zs sgd adfhmmhmf ne gdq rxlosnlr, vghbg lzcd mn cheedqdmbd. Zesdq 3 lnmsgr ne sqdzsldms, sgdqd gzr addm mn hloqnudldms hm rxlosnlr. Gdq rxlosnlr zqd ahkzsdqzk, zmc rgd qdonqsr mn aknncx chrbgzqfd.",
            "Z 56-xdzq-nkc lzm oqdrdmsr vhsg odqrhrsdms ahkzsdqzk mzrzk chrbgzqfd zmc aknbjzfd, z rdmrzshnm ne ezbhzk etkkmdrr zmc oqdrrtqd, z qdctbshnm hm rdmrd ne rldkk zmc fdmdqzk lzkzhrd enq 5 lnmsgr. Sgdqd hr mn aknncx chrbgzqfd, zmc gd hr nsgdqvhrd vdkk. Gd gzr zkqdzcx sqhdc mzrzk rzkhmd hqqhfzshnm, vghbg gzr oqnuhcdc rnld qdkhde ats mns qdrnkudc ghr rxlosnlr. Sgd rxlosnlr zqd zeedbshmf ghr rkddo zmc lzjhmf ghl eddk qtm cnvm, zmc gd zrjr enq xntq gdko sn qdrnkud sghr, zr hs hr rszqshmf sn zeedbs ghr vnqj."
        ],
        "answers": [
            "8",
            "9",
            "3"
        ],
        "notes": [
            "The correct answer is <b>refer on the urgent cancer pathway</b>. This man has unilateral nasal symptoms (a red flag when considering ENT presentations) and so warrants an urgent referral on the cancer pathway to exclude malignancy, as per NICE guidelines. <br /><br />Any of the other options would be inappropriate as, firstly, they would delay the necessary urgent referral, and secondly, if this turns out to be an underlying malignancy, none of the suggested treatment options would be effective for this condition. Therefore, this question requires you to recognise the red flag of unilateral nasal symptoms, which should trigger urgent referral on the rule-out cancer pathway.",
            "The correct answer is <b>refer to ENT</b>. Persistent symptoms of chronic rhinosinusitis, despite compliance with 3 months of treatment, are an indication to refer to ENT (urgency dependent on clinical judgement) as per NICE guidelines. She does not currently have any red flag symptoms that trigger an urgent cancer referral (bloody discharge, unilateral symptoms or facial swelling).<br /><br />We are told in this scenario that she has already tried intranasal steroids and saline douching for 3 months. This requires you to be familiar with the NICE CKS guidelines on management of chronic rhinosinusitis, which state that persistent symptoms after 3 months of treatment should trigger referral to an appropriate specialist. <br /><br /><b>Oral corticosteroids</b> is incorrect. The NICE CKS guidelines state that this treatment should not be started without consulting with a specialist, so selecting this answer, which does not specify this qualification, would be less appropriate than referring to ENT. <br /><br /><b>Intranasal decongestants</b> is incorrect. While this can be considered for short periods for chronic rhinosinusitis, where nasal blockage is particularly troublesome, this would not provide ongoing relief or treat the underlying process like corticosteroids will. Given that her symptoms are persistent after 3 months of treatment, it would be more appropriate to refer her to ENT for further management.<br /><br /><b>Intranasal corticosteroids</b> is incorrect; this treatment has already been adequately tried and has failed. <br /><br /><b>Expectant management</b> is incorrect. Once symptoms are ongoing for 3 months, it is less likely they will resolve on their own, plus these symptoms are likely to have a significant impact on her quality of life, and there are further treatments that can be tried under specialist guidance. <br /><br /><b>Saline nasal irrigation</b> is incorrect; this treatment has already been adequately tried and has failed. <br /><br /><b>Oral antihistamines</b> is incorrect. As discussed in the answer to question 3 below, this is chronic rhinosinusitis, not allergic rhinitis, and is not thought to be an allergy-related condition. The NICE CKS guidelines specifically state that antihistamines are not recommended for the management of chronic rhinosinusitis. <br /><br /><b>Intranasal antihistamines</b> is incorrect, for the same reasons as oral antihistamines discussed above. <br /><br /><b>Refer on the urgent cancer pathway</b> is incorrect. As mentioned, she has no red flag symptoms that would warrant an urgent referral. <br /><br /><b>Antibiotics</b> is incorrect. She has already tried a short course of antibiotics that did not work, and NICE CKS guidelines state antibiotics are not routinely needed, and that if longer courses are considered, this should be done by secondary care.",
            "The correct answer is <b>intranasal corticosteroids</b>. This man is presenting with symptoms consistent with chronic rhinosinusitis. The next most appropriate step would be to trial intranasal steroids for up to 3 months, in line with NICE guidelines. He has no red flag symptoms that would warrant referral, and as yet has not exhausted treatment options in primary care. <br /><br /><b>Oral corticosteroids</b> is incorrect. The NICE CKS guidelines state that intranasal corticosteroids, along with nasal douching, are the first-line treatments. Additionally, oral corticosteroids should not be started without consulting a specialist. <br /><br /><b>Intranasal decongestants</b> is incorrect. While this can be considered for short periods for chronic rhinosinusitis, where nasal blockage is particularly troublesome, this would not provide ongoing relief or treat the underlying process like corticosteroids will. Intranasal corticosteroids are also listed above decongestants in the guidelines. <br /><br /><b>Expectant management</b> is incorrect. Once symptoms are ongoing for 3 months, it is less likely they will resolve on their own, plus these symptoms are likely to have a significant impact on quality of life, and there are simple treatments that can be easily initiated with minimal side effects. <br /><br /><b>Saline nasal irrigation</b> is incorrect; this treatment has already been tried and appears insufficient. You could advise that this be continued alongside the intranasal corticosteroids.  <br /><br /><b>Oral antihistamines</b> is incorrect. The NICE CKS guidelines specifically state that antihistamines are not recommended for the management of chronic rhinosinusitis. For allergic rhinitis (also known as hay fever), however, this treatment can be effective and is recommended first-line. To differentiate these conditions, we need to consider the pattern, duration and triggers of symptoms. Allergic rhinitis is characterised by short-lived symptoms with prominent sneezing or itching triggered by an allergen, which resolve after exposure to the allergen has stopped. Chronic rhinosinusitis would present with persistent symptoms for 12 weeks or more, and more classically produces nasal obstruction, facial pressure, and significant nasal discharge. Sneezing and itching would be expected to be less common and less persistent symptoms in chronic rhinosinusitis.<br /><br /><b>Intranasal antihistamines</b> is incorrect, for the same reasons as oral antihistamines discussed above. <br /><br /><b>Refer on the urgent cancer pathway</b> is incorrect. As mentioned, she has no red flag symptoms that would warrant an urgent referral. <br /><br /><b>Refer to ENT</b> is incorrect. There are no features here that currently indicate referral. Though his symptoms have persisted for more than 3 months, the distinction in the recommendation for referral here is that the patient should have failed 3 months of treatment, which he has not yet done. <br /><br /><b>Antibiotics</b> is incorrect. NICE CKS guidelines state that antibiotics are not routinely needed, and that their use is better considered by secondary care. Though antibiotics are still often used, they are not the first-line treatment in the guidelines; therefore, intranasal corticosteroids would be more appropriate."
        ],
        "exam_specific_explanation": "",
        "question": "A 40-year-old man presents with persistent nasal discharge and blockage for the last 4 months. He has not had fevers and is otherwise well. When questioned more closely, he states it is almost always the left side only that is blocked. <br /><br />On examination, there is some rhinorrhoea from the left side, but otherwise nothing else of note.",
        "correct_answer": "8",
        "question_notes": "The correct answer is <b>refer on the urgent cancer pathway</b>. This man has unilateral nasal symptoms (a red flag when considering ENT presentations) and so warrants an urgent referral on the cancer pathway to exclude malignancy, as per NICE guidelines. <br /><br />Any of the other options would be inappropriate as, firstly, they would delay the necessary urgent referral, and secondly, if this turns out to be an underlying malignancy, none of the suggested treatment options would be effective for this condition. Therefore, this question requires you to recognise the red flag of unilateral nasal symptoms, which should trigger urgent referral on the rule-out cancer pathway.",
        "answer_order": "8",
        "answer": "8",
        "title": "Chronic rhinosinusitis",
        "body": "Chronic rhinosinusitis affects up to 1 in 10 people. It is generally defined as an inflammatory disorder of the paranasal sinuses and linings of the nasal passages that lasts 12 weeks or longer.<br /><br />Predisposing factors include:<br /><ul><li>atopy: hay fever, asthma</li><li>nasal obstruction e.g. Septal deviation or nasal polyps</li><li>recent local infection e.g. Rhinitis or dental extraction</li><li>swimming/diving</li><li>smoking</li></ul><br />Features<br /><ul><li>facial pain: typically frontal pressure pain which is worse on bending forward</li><li>nasal discharge: usually clear if allergic or vasomotor. Thicker, purulent discharge suggests secondary infection</li><li>nasal obstruction: e.g. 'mouth breathing'</li><li>post-nasal drip: may produce chronic cough</li></ul><br />Management of recurrent or chronic sinusitis<br /><ul><li>avoid allergen</li><li>intranasal corticosteroids</li><li><span class=\"concept\" data-cid=\"10862\">nasal irrigation with saline solution</span></li></ul><br />Red flags symptoms<br /><ul><li><span class=\"concept\" data-cid=\"10861\">unilateral symptoms</span></li><li>persistent symptoms despite compliance with 3 months of treatment</li><li>epistaxis</li></ul>",
        "notes_hash": "cf1d742e0f38e50f0c813c0b272bad1c",
        "knowledge_graph_node_id_link": 1506,
        "concept": "",
        "concept_percentile": 0,
        "concept_colour": "",
        "number_attempts": "109",
        "up_votes": "2",
        "down_votes": "1",
        "column_array": [
            0,
            "79",
            "85",
            "59",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "",
        "media": "<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/xH4lmriOzzc\" data-description=\"Sinusitis\" data-upvotes=\"5\" data-downvotes=\"1\" data-media=\"1269\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/xH4lmriOzzc/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/xH4lmriOzzc\" data-description=\"Sinusitis\" data-upvotes=\"5\" data-downvotes=\"1\" data-media=\"1269\">Sinusitis</a></td></tr><tr><td><span ><small>Osmosis - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_2245\" data-mediaid=\"2245\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_2245\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">5</span><button type=\"button\" style=\"\" id=\"media_dislike_2245\" data-mediaid=\"2245\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_2245\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">1</span></td></tr><tr><td>&nbsp;</td></tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/DJ10WqjCNjw\" data-description=\"Understanding Sinusitis\" data-upvotes=\"3\" data-downvotes=\"1\" data-media=\"1428\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/DJ10WqjCNjw/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/DJ10WqjCNjw\" data-description=\"Understanding Sinusitis\" data-upvotes=\"3\" data-downvotes=\"1\" data-media=\"1428\">Understanding Sinusitis</a></td></tr><tr><td><span ><small>Zero To Finals - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_2523\" data-mediaid=\"2523\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_2523\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">3</span><button type=\"button\" style=\"\" id=\"media_dislike_2523\" data-mediaid=\"2523\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_2523\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">1</span></td></tr></table>",
        "comment_count": 3,
        "concepts_for_notes": {
            "10861": {
                "concept_text": "Unilateral symptoms are a red flag for patients with chronic rhinosinusitis",
                "concept_percentile": "89"
            },
            "10862": {
                "concept_text": "Nasal irrigation with saline solution is a treatment option for chronic rhinosinusitis",
                "concept_percentile": "72"
            }
        },
        "optimisation_reason": ""
    },
    {
        "question_id": "4572_B_277",
        "new_question_id": "15259",
        "question_type": "0",
        "category": "2",
        "concept_id_link": "3461",
        "notes_id_link": "1_1046",
        "theme": "",
        "instruction": "",
        "options": [
            "",
            "Occuring in an elderly person",
            "Occuring under the nail",
            "History of trauma",
            "The lesion is slow growing",
            "Occurring on the sole of the foot",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "A 50-year-old man presents to the GP with a red spherical lesion that he would like looked at. Which of the following would point towards a diagnosis of a pyogenic granuloma over an amelanotic melanoma?",
            "",
            ""
        ],
        "answers": [
            "3",
            "0",
            "0"
        ],
        "notes": [
            "This question is asking for the differentiating features of pyogenic granuloma and an amelanotic malignant melanoma. Both of these look similar however it is often differentiated based off of a history of trauma. With a pyogenic granuloma commonly occurring at the site of a minor injury such as a splinter. <br /><br />An amelanotic melanoma, on the other hand, occurs spontaneously, often on the sole of the foot or under a nail. They grow more slowly with no history of trauma. Also, amelanotic melanomas are more common in the elderly than pyogenic granulomas but are particularly rare in childhood",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "A 50-year-old man presents to the GP with a red spherical lesion that he would like looked at. Which of the following would point towards a diagnosis of a pyogenic granuloma over an amelanotic melanoma?",
        "correct_answer": "3",
        "question_notes": "This question is asking for the differentiating features of pyogenic granuloma and an amelanotic malignant melanoma. Both of these look similar however it is often differentiated based off of a history of trauma. With a pyogenic granuloma commonly occurring at the site of a minor injury such as a splinter. <br /><br />An amelanotic melanoma, on the other hand, occurs spontaneously, often on the sole of the foot or under a nail. They grow more slowly with no history of trauma. Also, amelanotic melanomas are more common in the elderly than pyogenic granulomas but are particularly rare in childhood",
        "answer_order": "3",
        "answer": "3",
        "title": "Pyogenic granuloma",
        "body": "Pyogenic granuloma is a relatively common benign skin lesion. The name is confusing as they are neither true granulomas nor pyogenic in nature. There are multiple alternative names but perhaps 'eruptive haemangioma' is the most useful.<br /><br />The cause of pyogenic granuloma is not known but a number of factors are linked:<br /><ul><li>trauma</li><li>pregnancy</li><li>more common in women and young adults</li></ul><br />Features<br /><ul><li>most common sites are head/neck, upper trunk and hands. Lesions in the oral mucosa are common in pregnancy</li><li>initially small red/brown spot</li><li>rapidly progress within days to weeks forming raised, red/brown lesions which are often spherical in shape</li><li>the lesions may bleed profusely or ulcerate</li></ul><br /><div class=\"container\"><div class=\"row\"><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ddd931.jpg\" data-fancybox=\"gallery\" data-caption=\"Pyogenic granuloma\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ddd931.jpg\" alt=\"\" /></a></div><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ddd097b.jpg\" data-fancybox=\"gallery\" data-caption=\"Pyogenic granuloma\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ddd097.jpg\" alt=\"\" /></a></div><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ddd098b.jpg\" data-fancybox=\"gallery\" data-caption=\"Pyogenic granuloma\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ddd098.jpg\" alt=\"\" /></a></div></div></div><br />Management<br /><ul><li>lesions associated with pregnancy often resolve spontaneously post-partum</li><li>other lesions usually persist. Removal methods include curettage and cauterisation, cryotherapy, excision</li></ul>",
        "notes_hash": "b57684e97c42273deb630d3092a9be04",
        "knowledge_graph_node_id_link": 11095,
        "concept": "A pyogenic granuloma may mimic amelanotic melanoma but can be differentiated based on a history of trauma<br />",
        "concept_percentile": "88",
        "concept_colour": "rgb(61,255,0)",
        "number_attempts": "5560",
        "up_votes": "4",
        "down_votes": "3",
        "column_array": [
            0,
            "241",
            "246",
            "3777",
            "918",
            "378",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "<table style='width:100%'><tr><td>DermNet NZ</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_79\" data-linkid=\"79\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_79\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">14</span><button type=\"button\" style=\"\" id=\"link_dislike_79\" data-linkid=\"79\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_79\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">3</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https://www.dermnetnz.org/topics/pyogenic-granuloma/\">Pyogenic granuloma</a></td></tr></table>",
        "media": "",
        "comment_count": 1,
        "concepts_for_notes": [],
        "optimisation_reason": ""
    },
    {
        "question_id": "999_B_1405",
        "new_question_id": "59537",
        "question_type": "0",
        "category": "6",
        "concept_id_link": "1720",
        "notes_id_link": "1_1797",
        "theme": "Identifying the affected nerve root in lumbar radiculopathy",
        "instruction": "",
        "options": [
            "",
            "L3",
            "L4",
            "L5",
            "S1",
            "S2",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "A 42-year-old construction worker presents to his GP with a 3-week history of right-sided lower back pain radiating down the back of his leg to the lateral aspect of his foot. The pain is worse when sitting. On examination, there is reduced sensation over the lateral aspect of his right foot, weakness in plantar flexion, and a diminished right ankle reflex. Straight leg raise on the right side is limited to 30 degrees due to pain.<br /><br />What is the most likely nerve root affected?",
            "",
            ""
        ],
        "answers": [
            "4",
            "",
            ""
        ],
        "notes": [
            "<b>S1</b> nerve root compression is the correct diagnosis based on the clinical presentation. The patient demonstrates the classic triad of S1 radiculopathy: sensory loss over the posterolateral aspect of the leg and lateral aspect of the foot, weakness in plantar flexion of the foot, and a reduced ankle reflex. The positive straight leg raise test (limited to 30 degrees due to pain) is consistent with sciatic nerve irritation, which commonly occurs with S1 compression. The pain distribution following the posterolateral leg to the lateral foot is a typical S1 dermatomal pattern. Additionally, the pain worsening when sitting is characteristic of disc prolapse affecting the S1 nerve root, as this position increases pressure on the intervertebral disc.<br /><br /><b>L3</b> nerve root compression presents differently, with sensory loss over the anterior thigh, weakness in hip flexion, knee extension and hip adduction, and a reduced knee reflex. The femoral stretch test would be positive rather than the sciatic stretch test. The distribution of pain and neurological deficits in this case does not match L3 radiculopathy.<br /><br /><b>L4</b> nerve root compression typically causes sensory loss over the anterior aspect of the knee extending to the medial malleolus. Patients would demonstrate weakness in knee extension and hip adduction with a reduced knee reflex. The femoral stretch test would be positive. The clinical findings in this scenario, particularly the lateral foot sensory loss and reduced ankle reflex, are not consistent with L4 involvement.<br /><br /><b>L5</b> nerve root compression presents with sensory loss over the dorsum of the foot and weakness in foot and big toe dorsiflexion. Importantly, reflexes typically remain intact with L5 radiculopathy. While the sciatic stretch test would be positive, the patient's presentation with plantar flexion weakness and reduced ankle reflex points away from L5 involvement.<br /><br /><b>S2</b> nerve root compression is less common and typically affects the posterior thigh, posterior calf, and plantar aspect of the foot. While there may be some overlap with S1 symptoms, pure S2 radiculopathy would typically affect the posterior heel more prominently and might cause issues with bowel or bladder function in severe cases. The clinical picture described is more consistent with S1 than S2 involvement.",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "A 42-year-old construction worker presents to his GP with a 3-week history of right-sided lower back pain radiating down the back of his leg to the lateral aspect of his foot. The pain is worse when sitting. On examination, there is reduced sensation over the lateral aspect of his right foot, weakness in plantar flexion, and a diminished right ankle reflex. Straight leg raise on the right side is limited to 30 degrees due to pain.<br /><br />What is the most likely nerve root affected?",
        "correct_answer": "4",
        "question_notes": "<b>S1</b> nerve root compression is the correct diagnosis based on the clinical presentation. The patient demonstrates the classic triad of S1 radiculopathy: sensory loss over the posterolateral aspect of the leg and lateral aspect of the foot, weakness in plantar flexion of the foot, and a reduced ankle reflex. The positive straight leg raise test (limited to 30 degrees due to pain) is consistent with sciatic nerve irritation, which commonly occurs with S1 compression. The pain distribution following the posterolateral leg to the lateral foot is a typical S1 dermatomal pattern. Additionally, the pain worsening when sitting is characteristic of disc prolapse affecting the S1 nerve root, as this position increases pressure on the intervertebral disc.<br /><br /><b>L3</b> nerve root compression presents differently, with sensory loss over the anterior thigh, weakness in hip flexion, knee extension and hip adduction, and a reduced knee reflex. The femoral stretch test would be positive rather than the sciatic stretch test. The distribution of pain and neurological deficits in this case does not match L3 radiculopathy.<br /><br /><b>L4</b> nerve root compression typically causes sensory loss over the anterior aspect of the knee extending to the medial malleolus. Patients would demonstrate weakness in knee extension and hip adduction with a reduced knee reflex. The femoral stretch test would be positive. The clinical findings in this scenario, particularly the lateral foot sensory loss and reduced ankle reflex, are not consistent with L4 involvement.<br /><br /><b>L5</b> nerve root compression presents with sensory loss over the dorsum of the foot and weakness in foot and big toe dorsiflexion. Importantly, reflexes typically remain intact with L5 radiculopathy. While the sciatic stretch test would be positive, the patient's presentation with plantar flexion weakness and reduced ankle reflex points away from L5 involvement.<br /><br /><b>S2</b> nerve root compression is less common and typically affects the posterior thigh, posterior calf, and plantar aspect of the foot. While there may be some overlap with S1 symptoms, pure S2 radiculopathy would typically affect the posterior heel more prominently and might cause issues with bowel or bladder function in severe cases. The clinical picture described is more consistent with S1 than S2 involvement.",
        "answer_order": "4",
        "answer": "4",
        "title": "Lower back pain: prolapsed disc",
        "body": "A prolapsed lumbar disc usually produces clear <span class=\"concept\" data-cid=\"10511\">dermatomal leg pain</span> associated with neurological deficits.<br /><br />Features<br /><ul><li>leg pain usually worse than back</li><li>pain often worse when sitting</li></ul><br />The table below demonstrates the expected features according to the level of compression:<br /><br /><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid1\" ><thead><tr><th><b>Site of compression</b></th><th><b>Features</b></th></tr></thead><tbody><tr><td><b><span class=\"concept\" data-cid=\"12042\">L3 nerve root compression</span></b></td><td>Sensory loss over anterior thigh<br />Weak hip flexion, knee extension and hip adduction<br />Reduced knee reflex<br />Positive femoral stretch test</td></tr><tr><td><b><span class=\"concept\" data-cid=\"12043\">L4 nerve root compression</span></b></td><td>Sensory loss anterior aspect of knee and medial malleolus<br />Weak knee extension and hip adduction<br />Reduced knee reflex<br />Positive femoral stretch test</td></tr><tr><td><b>L5 nerve root compression</b></td><td><span class=\"concept\" data-cid=\"447\">Sensory loss dorsum of foot</span><br /><span class=\"concept\" data-cid=\"4915\">Weakness in foot and big toe dorsiflexion</span><br /><span class=\"concept\" data-cid=\"4915\">Reflexes intact</span><br />Positive sciatic nerve stretch test</td></tr><tr><td><b>S1 nerve root compression</b></td><td><span class=\"concept\" data-cid=\"1720\">Sensory loss posterolateral aspect of leg and lateral aspect of foot</span><br /><span class=\"concept\" data-cid=\"1720\">Weakness in plantar flexion of foot</span><br /><span class=\"concept\" data-cid=\"1720\">Reduced ankle reflex</span><br />Positive sciatic nerve stretch test</td></tr></tbody></table></div><br />Management<br /><ul><li>similar to that of other musculoskeletal lower back pain: analgesia, physiotherapy, exercises<ul><li>NICE recommend using the same drugs as for back pain without sciatica symptoms i.e. first-line is NSAIDs +/- proton pump inhibitors rather than using neuropathic analgesia (e.g. duloxetine)</li></ul></li><li><span class=\"concept\" data-cid=\"10512\">if symptoms persist e.g. after 4-6 weeks) then referral for consideration of MRI is appropriate</span></li></ul>",
        "notes_hash": "0e7d8ebeb49a8f91855865ffeb394b6d",
        "knowledge_graph_node_id_link": 1447,
        "concept": "S1 lesion features = Sensory loss of posterolateral aspect of leg and lateral aspect of foot,  weakness in plantar flexion of foot, reduced ankle reflex, positive sciatic nerve stretch test",
        "concept_percentile": "73",
        "concept_colour": "rgb(137,255,0)",
        "number_attempts": "4247",
        "up_votes": "4",
        "down_votes": "4",
        "column_array": [
            0,
            "93",
            "377",
            "1068",
            "2517",
            "192",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "",
        "media": "<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/VYj-JfX0wT0\" data-description=\"Sciatica\" data-upvotes=\"13\" data-downvotes=\"2\" data-media=\"655\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/VYj-JfX0wT0/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/VYj-JfX0wT0\" data-description=\"Sciatica\" data-upvotes=\"13\" data-downvotes=\"2\" data-media=\"655\">Sciatica</a></td></tr><tr><td><span ><small>Osmosis - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1128\" data-mediaid=\"1128\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_1128\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">13</span><button type=\"button\" style=\"\" id=\"media_dislike_1128\" data-mediaid=\"1128\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_1128\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">2</span></td></tr></table>",
        "comment_count": 1,
        "concepts_for_notes": {
            "447": {
                "concept_text": "L5 lesion features = loss of foot dorsiflexion + sensory loss dorsum of the foot",
                "concept_percentile": "53"
            },
            "1720": {
                "concept_text": "S1 lesion features = Sensory loss of posterolateral aspect of leg and lateral aspect of foot,  weakness in plantar flexion of foot, reduced ankle reflex, positive sciatic nerve stretch test",
                "concept_percentile": "73"
            },
            "10511": {
                "concept_text": "Nerve root pain can be distinguished from other pain in the leg by the dermatomal distribution and an associated neurological deficit",
                "concept_percentile": "54"
            },
            "10512": {
                "concept_text": "A referral for sciatica is appropriate after 4-6 weeks of conservative treatment (analgesia and physiotherapy) has failed",
                "concept_percentile": "86"
            }
        },
        "optimisation_reason": ""
    },
    {
        "question_id": "1_B_1876",
        "new_question_id": "4043",
        "question_type": "0",
        "category": "3",
        "concept_id_link": "0",
        "notes_id_link": "1_1692",
        "theme": "",
        "instruction": "",
        "options": [
            "",
            "Add sitagliptin",
            "Make no changes to his medication",
            "Add empagliflozin",
            "Add pioglitazone",
            "Add exenatide",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "A 64-year-old man is reviewed in clinic. He has a history of ischaemic heart disease and was diagnosed with type 2 diabetes mellitus around 12 months ago. At this time of diagnosis his HbA1c was 7.6% (60 mmol/mol) and he was started on metformin which was titrated up to a dose of 1g bd. The most recent bloods show a HbA1c of 6.8% (51 mmol/mol). He has just retired from working in the IT industry and his body mass index (BMI) today is 28 kg/m\u00b2. His other medication is as follows:<br /><br />Atorvastatin 80mg on<br />Aspirin 75mg od<br />Bisoprolol 2.5 mg od<br />Ramipril 5mg od<br /><br />What is the most appropriate next step?",
            "",
            ""
        ],
        "answers": [
            "3",
            "0",
            "0"
        ],
        "notes": [
            "Normally NICE recommend we only add another drug if the HbA1c has risen to >= 58 mmol/mol (7.5%) at this stage. However, as this patient has established cardiovascular disease he should also be given an SGLT-2 inhibitor (e.g. empagliflozin) in addition to metformin.",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "A 64-year-old man is reviewed in clinic. He has a history of ischaemic heart disease and was diagnosed with type 2 diabetes mellitus around 12 months ago. At this time of diagnosis his HbA1c was 7.6% (60 mmol/mol) and he was started on metformin which was titrated up to a dose of 1g bd. The most recent bloods show a HbA1c of 6.8% (51 mmol/mol). He has just retired from working in the IT industry and his body mass index (BMI) today is 28 kg/m\u00b2. His other medication is as follows:<br /><br />Atorvastatin 80mg on<br />Aspirin 75mg od<br />Bisoprolol 2.5 mg od<br />Ramipril 5mg od<br /><br />What is the most appropriate next step?",
        "correct_answer": "3",
        "question_notes": "Normally NICE recommend we only add another drug if the HbA1c has risen to >= 58 mmol/mol (7.5%) at this stage. However, as this patient has established cardiovascular disease he should also be given an SGLT-2 inhibitor (e.g. empagliflozin) in addition to metformin.",
        "answer_order": "3",
        "answer": "3",
        "title": "Diabetes mellitus: management of type 2",
        "body": "NICE updated its guidance on the management of type 2 diabetes mellitus (T2DM) in 2022. This update reflected the advances in drug therapy and improved evidence regarding newer therapies such as SGLT-2 inhibitors.<br /><br /><div class='alert alert-warning'>It's worthwhile thinking of the average patient who is taking metformin for T2DM, you can titrate up metformin and encourage lifestyle changes to aim for a HbA1c of <span class=\"concept\" data-cid=\"9108\">48 mmol/mol</span> (6.5%), but should only add a second drug if the HbA1c rises to <span class=\"concept\" data-cid=\"9109\">58 mmol/mol</span> (7.5%)<br /></div><br /><br />Dietary advice<br /><ul><li>encourage high fibre, low glycaemic index sources of carbohydrates</li><li>include low-fat dairy products and oily fish</li><li>control the intake of foods containing saturated fats and trans fatty acids</li><li>limited substitution of sucrose-containing foods for other carbohydrates is allowable, but care should be taken to avoid excess energy intake</li><li>discourage the use of foods marketed specifically at people with diabetes</li><li>initial target weight loss in an overweight person is 5-10%</li></ul><br /><br /><h5 class='notes-heading'>HbA1c targets</h5><br />This is an area which has changed in 2015<br /><ul><li>individual targets should be agreed with patients to encourage motivation</li><li>HbA1c should be checked every 3-6 months until stable, then 6 monthly</li><li>NICE encourage us to consider relaxing targets on <i>'a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes'</i></li><li>in 2015 the guidelines changed so HbA1c targets are now dependent on treatment:</li></ul><br /><h6 class='notes-subheading'>Lifestyle or single-drug treatment</h6><br /><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid1\" ><thead><tr><th>Management of T2DM</th><th>HbA1c target</th></tr></thead><tbody><tr><td>Lifestyle</td><td><span class=\"concept\" data-cid=\"9108\">48 mmol/mol</span> (6.5%)</td></tr><tr><td>Lifestyle + metformin</td><td><span class=\"concept\" data-cid=\"9108\">48 mmol/mol</span> (6.5%)</td></tr><tr><td>Includes any drug which may cause hypoglycaemia (e.g. lifestyle + sulfonylurea)</td><td>53 mmol/mol (7.0%)</td></tr></tbody></table></div><br />Practical examples<br /><ul><li>a patient is newly diagnosed with HbA1c and wants to try lifestyle treatment first. You agree on a target of 48 mmol/mol (6.5%)</li><li>you review a patient 6 months after starting metformin. His HbA1c is 51 mmol/mol (6.8%). You increase his metformin from 500mg bd to 500mg tds and reinforce lifestyle factors</li></ul><br /><h6 class='notes-subheading'>Patient already on treatment</h6><br /><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid2\" ><thead><tr><th>Management of T2DM</th><th>HbA1c target</th></tr></thead><tbody><tr><td>Already on one drug, but HbA1c has risen to <span class=\"concept\" data-cid=\"9109\">58 mmol/mol</span> (7.5%)</td><td>53 mmol/mol (7.0%)</td></tr></tbody></table></div><br /><h5 class='notes-heading'>Initial drug therapy</h5><br /><CENTER><table><tr><td align = 'left' colspan='2'><a data-fancybox class='fancybox' rel='group' href='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd928b.png'><img class='ajaximage' src='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd928.png'/></a></td></tr><tr><td valign='top' align='left'></td><td align='right'><a data-fancybox class='fancybox lbmagglasslink' rel='group' href='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd928b.png'><img src='https://d32xxyeh8kfs8k.cloudfront.net/css/images/mag_glass.png'/></a></td></tr></table></CENTER><div class='imagetext'>Simplified initial management of type 2 diabetes mellitus</div><br /><span class=\"concept\" data-cid=\"9107\">Metformin remains the first-line drug</span> of choice in type 2 diabetes mellitus.<br /><ul><li>metformin should be titrated up slowly to minimise the possibility of gastrointestinal upset</li><li>if standard-release metformin is not tolerated then modified-release metformin should be trialled</li></ul><br /><span class=\"concept\" data-cid=\"11772\">SGLT-2 inhibitors</span><br /><ul><li>should also be given in addition to metformin if any of the following apply:<ul><li>the patient has a high risk of developing cardiovascular disease (CVD, e.g. QRISK \u2265 10%)</li><li>the patient has established CVD</li><li>the patient has chronic heart failure</li></ul></li><li><span class=\"concept\" data-cid=\"11773\">metformin should be established and titrated up before introducing the SGLT-2 inhibitor</span></li><li><span class=\"concept\" data-cid=\"11774\">SGLT-2 inhibitors should also be started at any point if a patient develops CVD (e.g. is diagnosed with ischaemic heart disease), a QRISK \u2265 10% or chronic heart failure</span></li></ul><br />If metformin is contraindicated<br /><ul><li>if the patient has a risk of CVD, established CVD or chronic heart failure:<ul><li><span class=\"concept\" data-cid=\"11775\">SGLT-2 monotherapy</span></li></ul></li><li>if the patient doesn't have a risk of CVD, established CVD or chronic heart failure:<ul><li><span class=\"concept\" data-cid=\"11776\">DPP-4 inhibitor or pioglitazone or a sulfonylurea</span></li><li>SGLT-2 may be used if certain NICE criteria are met</li></ul></li></ul><br /><br /><h5 class='notes-heading'>Further drug therapy if HbA1c targets are not met</h5><br /><CENTER><table><tr><td align = 'left' colspan='2'><a data-fancybox class='fancybox' rel='group' href='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd929b.png'><img class='ajaximage' src='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd929.png'/></a></td></tr><tr><td valign='top' align='left'></td><td align='right'><a data-fancybox class='fancybox lbmagglasslink' rel='group' href='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd929b.png'><img src='https://d32xxyeh8kfs8k.cloudfront.net/css/images/mag_glass.png'/></a></td></tr></table></CENTER><div class='imagetext'>Simplified further management of type 2 diabetes mellitus if HbA1c targets are not met</div><br />If the HbA1c has risen to 58 mmol/mol (7.5%) then further treatment is indicated. Given the large number of drug therapy options, medication choices depend on individual clinical circumstances (comorbidities, contraindications, weight) and patient preference.<br /><br /><h6 class='notes-subheading'>Second-line therapy</h6><br /><span class=\"concept\" data-cid=\"11777\">Dual therapy - add one of the following:</span><br /><ul><li>metformin + DPP-4 inhibitor</li><li>metformin + pioglitazone</li><li>metformin + sulfonylurea</li><li>metformin + SGLT-2 inhibitor (if NICE criteria met)</li></ul><br /><h6 class='notes-subheading'>Third-line therapy</h6><br /><span class=\"concept\" data-cid=\"11395\">If a patient does not achieve control on dual therapy then the following options are possible:</span><br /><ul><li>metformin + DPP-4 inhibitor + sulfonylurea</li><li>metformin  + pioglitazone + sulfonylurea</li><li>metformin + (pioglitazone or sulfonylurea or DPP-4 inhibitor) + SGLT-2 if certain NICE criteria are met</li><li>insulin-based treatment</li></ul><br /><h6 class='notes-subheading'>Further therapy</h6><br />If triple therapy is not effective or tolerated consider <span class=\"concept\" data-cid=\"11396\">switching one of the drugs for a GLP-1 mimetic</span>:<br /><ul><li>BMI \u2265 35 kg/m\u00b2 and specific psychological or other medical problems associated with obesity or</li><li>BMI < 35 kg/m\u00b2 and for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities</li><li>only continue if there is a reduction of at least 11 mmol/mol [1.0%] in HbA1c and a weight loss of at least 3% of initial body weight in 6 months</li></ul><br />GLP-1 mimetics should only be added to insulin under specialist care<br /><br />Starting insulin<br /><ul><li>metformin should be continued. In terms of other drugs NICE advice: <i>'Review the continued need for other blood glucose-lowering therapies'</i></li><li>NICE recommend starting with human NPH insulin (isophane, intermediate-acting) taken at bed-time or twice daily according to need</li></ul><br />Practical examples<br /><ul><li>you review an established type 2 diabetic on maximum dose metformin. Her HbA1c is 55 mmol/mol (7.2%). You do not add another drug as she has not reached the threshold of 58 mmol/mol (7.5%)</li><li>a type 2 diabetic is found to have an HbA1c of 62 mmol/mol (7.8%) at annual review. They are currently on maximum dose metformin. You elect to add a sulfonylurea</li></ul><br /><br /><h5 class='notes-heading'>Risk factor modification</h5><br />Hypertension<br /><ul><li><span class=\"concept\" data-cid=\"399\"><b>blood pressure targets are the same as for patients without type 2 diabetes</b> (see table below)</span></li><li>ACE inhibitors or angiotensin II receptor blockers (ARB) are first-line<ul><li>an <span class=\"concept\" data-cid=\"11206\">ARB is preferred if the patient has a black African or African-Caribbean</span> family origin</li></ul></li></ul><br /><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid3\" ><thead><tr><th></th><th><b>Clinic BP</b></th><th><b>ABPM / HBPM</b></th></tr></thead><tbody><tr><td><b>Age < 80 years</b></td><td>140/90 mmHg</td><td>135/85 mmHg</td></tr><tr><td><b>Age > 80 years</b></td><td>150/90 mmHg</td><td>145/85 mmHg</td></tr></tbody></table></div><br />Antiplatelets<br /><ul><li>should not be offered unless a patient has existing cardiovascular disease</li></ul><br />Lipids<br /><ul><li>following the 2014 NICE lipid modification guidelines only patients with a 10-year cardiovascular risk > 10% (using QRISK2) should be offered a statin. The first-line statin of choice is atorvastatin 20mg on</li></ul><br /><CENTER><table><tr><td align = 'left' colspan='2'><a data-fancybox class='fancybox' rel='group' href='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd915b.png'><img class='ajaximage' src='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd915.png'/></a></td></tr><tr><td valign='top' align='left'></td><td align='right'><a data-fancybox class='fancybox lbmagglasslink' rel='group' href='https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd915b.png'><img src='https://d32xxyeh8kfs8k.cloudfront.net/css/images/mag_glass.png'/></a></td></tr></table></CENTER><div class='imagetext'>Graphic showing choice of statin.</div>",
        "notes_hash": "ca06d8c38ddc0f626be19075164b9bce",
        "knowledge_graph_node_id_link": 10924,
        "concept": "",
        "concept_percentile": 0,
        "concept_colour": "",
        "number_attempts": "7047",
        "up_votes": "112",
        "down_votes": "48",
        "column_array": [
            0,
            "787",
            "2024",
            "4008",
            "145",
            "83",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "<table style='width:100%'><tr><td>SIGN</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_721\" data-linkid=\"721\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_721\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">36</span><button type=\"button\" style=\"\" id=\"link_dislike_721\" data-linkid=\"721\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_721\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">47</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https://www.sign.ac.uk/assets/qrg116.pdf\">2010 Management of diabetes</a></td></tr></table><br><br><table style='width:100%'><tr><td>NICE</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_457\" data-linkid=\"457\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_457\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">34</span><button type=\"button\" style=\"\" id=\"link_dislike_457\" data-linkid=\"457\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_457\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">43</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https://www.nice.org.uk/guidance/CG181/chapter/1-Recommendations\">2014 Lipid modification guidelines</a></td></tr></table><br><br><table style='width:100%'><tr><td>NICE</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_911\" data-linkid=\"911\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_911\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">56</span><button type=\"button\" style=\"\" id=\"link_dislike_911\" data-linkid=\"911\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_911\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">54</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https://www.nice.org.uk/guidance/ng28/chapter/Recommendations\">2022 Type 2 diabetes guidelines</a></td></tr></table><br><br><table style='width:100%'><tr><td>7 minute medics</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_1395\" data-linkid=\"1395\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_1395\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">44</span><button type=\"button\" style=\"\" id=\"link_dislike_1395\" data-linkid=\"1395\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_1395\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">32</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https://anchor.fm/7minutemedics/episodes/Episode-2---Type-2-Diabetes-e2ebql\">Basics of type 2 diabetes - podcast</a></td></tr></table>",
        "media": "<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/4Y7wdX7iEAY\" data-description=\"Type 2 diabetes agents and their mechanism of action\" data-upvotes=\"51\" data-downvotes=\"6\" data-media=\"694\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/4Y7wdX7iEAY/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/4Y7wdX7iEAY\" data-description=\"Type 2 diabetes agents and their mechanism of action\" data-upvotes=\"51\" data-downvotes=\"6\" data-media=\"694\">Type 2 diabetes agents and their mechanism of action</a></td></tr><tr><td><span ><small>Brandl's Basics - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1195\" data-mediaid=\"1195\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_1195\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">51</span><button type=\"button\" style=\"\" id=\"media_dislike_1195\" data-mediaid=\"1195\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_1195\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">6</span></td></tr><tr><td>&nbsp;</td></tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/APHeDOkJKQ0\" data-description=\" Pharmacology of drugs used to treat type 2 diabetes\" data-upvotes=\"9\" data-downvotes=\"6\" data-media=\"693\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/APHeDOkJKQ0/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/APHeDOkJKQ0\" data-description=\" Pharmacology of drugs used to treat type 2 diabetes\" data-upvotes=\"9\" data-downvotes=\"6\" data-media=\"693\"> Pharmacology of drugs used to treat type 2 diabetes</a></td></tr><tr><td><span ><small>Brandl's Basics - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1194\" data-mediaid=\"1194\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_1194\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">9</span><button type=\"button\" style=\"\" id=\"media_dislike_1194\" data-mediaid=\"1194\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_1194\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">6</span></td></tr><tr><td>&nbsp;</td></tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/W0KPwTy0W9k\" data-description=\"Diabetes Type II Pathophysiology\" data-upvotes=\"4\" data-downvotes=\"4\" data-media=\"400\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/W0KPwTy0W9k/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/W0KPwTy0W9k\" data-description=\"Diabetes Type II Pathophysiology\" data-upvotes=\"4\" data-downvotes=\"4\" data-media=\"400\">Diabetes Type II Pathophysiology</a></td></tr><tr><td><span ><small>Armando Hasudungan - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_685\" data-mediaid=\"685\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_685\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">4</span><button type=\"button\" style=\"\" id=\"media_dislike_685\" data-mediaid=\"685\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_685\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">4</span></td></tr></table>",
        "comment_count": 6,
        "concepts_for_notes": {
            "9108": {
                "concept_text": "The standard HbA1c target in type 2 diabetes mellitus is 48 mmol/mol",
                "concept_percentile": "81"
            },
            "11395": {
                "concept_text": "TD2M already on 2 drugs - if HbA1c > 58 mmol/mol then one of the following should be offered:\n   - metformin + DPP-4 inhibitor + sulfonylurea\n   - metformin  + pioglitazone + sulfonylurea\n   - metformin + (pioglitazone or sulfonylurea or DPP-4 inhibitor) + SGLT-2 if certain NICE criteria are met\n   - insulin-based treatment",
                "concept_percentile": "73"
            },
            "11396": {
                "concept_text": "TD2M: if a triple combination of drugs has failed to reduce HbA1c then switching one of the drugs for a GLP-1 mimetic is recommended, particularly if the BMI > 35",
                "concept_percentile": "76"
            },
            "11772": {
                "concept_text": "SGLT-2 inhibitors should be used in addition to metformin as initial therapy for T2DM if CVD, high-risk of CVD or chronic heart failure",
                "concept_percentile": "65"
            },
            "11773": {
                "concept_text": "If starting an SGLT-2 as initial therapy for T2DM then ensure metformin is titrated up first",
                "concept_percentile": "91"
            },
            "11774": {
                "concept_text": "In patients with T2DM, SGLT-2 should be introduced at any point they develop CVD, a high risk of CVD or chronic heart failure",
                "concept_percentile": "66"
            },
            "11775": {
                "concept_text": "T2DM initial therapy: if metformin is contraindicated + patient has a risk of CVD, established CVD or chronic heart failure --> SGLT-2 monotherapy",
                "concept_percentile": "88"
            },
            "11776": {
                "concept_text": "T2DM initial therapy: if metformin is contraindicated (and no risk of CVD, established CVD or chronic heart failure) --> choice of DPP-4 inhibitor or Pioglitazone or Sulfonylurea or even SGLT-2 (if NICE criteria met)",
                "concept_percentile": "89"
            },
            "11777": {
                "concept_text": "T2DM on metformin, if HbA1c has risen to 58 mmol/mol then one of the following should be offered depending on the individual clinical scenario:\n   - DPP-4 inhibitor\n   - pioglitazone\n   - sulfonylurea\n   - SGLT-2 inhibitor (if NICE criteria met)",
                "concept_percentile": "74"
            }
        },
        "optimisation_reason": ""
    },
    {
        "question_id": "1_B_136",
        "new_question_id": "5334",
        "question_type": "0",
        "category": "2",
        "concept_id_link": "0",
        "notes_id_link": "1_1836",
        "theme": "",
        "instruction": "",
        "options": [
            "",
            "Desmoplastic trichoepithelioma",
            "Squamous cell carcinoma",
            "Impetigo",
            "Basal cell carcinoma",
            "Actinic keratosis",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "A 62-year-old man presents with a lesion on the right side of his nose. He is unsure how long it has been there.<br /><br /><CENTER><table><tr><td align = 'left' colspan='2'><img class='ajaximage' src = 'https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/img069.jpg' /></td></tr><tr><td valign='top' align='left'></td><td align='right'></td></tr></table></CENTER><br />What is the most likely diagnosis?",
            "",
            ""
        ],
        "answers": [
            "4",
            "",
            ""
        ],
        "notes": [
            "The rolled, pearly edges with telangiectasia surrounding a central crater make basal cell carcinoma the most likely diagnosis.",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "A 62-year-old man presents with a lesion on the right side of his nose. He is unsure how long it has been there.<br /><br /><CENTER><table><tr><td align = 'left' colspan='2'><img class='ajaximage' src = 'https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/img069.jpg' /></td></tr><tr><td valign='top' align='left'></td><td align='right'></td></tr></table></CENTER><br />What is the most likely diagnosis?",
        "correct_answer": "4",
        "question_notes": "The rolled, pearly edges with telangiectasia surrounding a central crater make basal cell carcinoma the most likely diagnosis.",
        "answer_order": "4",
        "answer": "4",
        "title": "Basal cell carcinoma",
        "body": "Basal cell carcinoma (BCC) is one of the three main types of skin cancer. Lesions are also known as rodent ulcers and are characterised by slow-growth and local invasion. Metastases are extremely rare. BCC is the most common type of cancer in the Western world.<br /><br />Features<br /><ul><li>many types of BCC are described. The most common type is nodular BCC, which is described here</li><li>sun-exposed sites, especially the head and neck account for the majority of lesions</li><li>initially a pearly, flesh-coloured papule with telangiectasia</li><li>may later ulcerate leaving a central 'crater'</li></ul><br /><div class=\"container\"><div class=\"row\"><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/img069.jpg\" data-fancybox=\"gallery\" data-caption=\"Basal cell carcinoma\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/img069.jpg\" alt=\"\" /></a></div><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/img070.jpg\" data-fancybox=\"gallery\" data-caption=\"Basal cell carcinoma\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/img070.jpg\" alt=\"\" /></a></div><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ddd932b.jpg\" data-fancybox=\"gallery\" data-caption=\"Basal cell carcinoma\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ddd932.jpg\" alt=\"\" /></a></div><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ddd071b.jpg\" data-fancybox=\"gallery\" data-caption=\"Basal cell carcinoma\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ddd071.jpg\" alt=\"\" /></a></div></div><div class=\"row\"><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ddd072b.jpg\" data-fancybox=\"gallery\" data-caption=\"Basal cell carcinoma\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ddd072.jpg\" alt=\"\" /></a></div><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ddd073b.jpg\" data-fancybox=\"gallery\" data-caption=\"Basal cell carcinoma\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/ddd073.jpg\" alt=\"\" /></a></div></div></div>   <br />Referral<br /><ul><li>generally, if a BCC is suspected, <span class=\"concept\" data-cid=\"1701\">a routine referral should be made </span></li></ul><br />Management options:<br /><ul><li>surgical removal</li><li>curettage</li><li>cryotherapy</li><li>topical cream: imiquimod, fluorouracil </li><li>radiotherapy</li></ul>",
        "notes_hash": "4d9d277b7e075ede4873f7faa06f8c7e",
        "knowledge_graph_node_id_link": 10954,
        "concept": "",
        "concept_percentile": 0,
        "concept_colour": "",
        "number_attempts": "5952",
        "up_votes": "35",
        "down_votes": "25",
        "column_array": [
            0,
            "62",
            "915",
            "6",
            "4893",
            "75",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "<table style='width:100%'><tr><td>DermNet NZ</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_756\" data-linkid=\"756\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_756\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">18</span><button type=\"button\" style=\"\" id=\"link_dislike_756\" data-linkid=\"756\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_756\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">8</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https://www.dermnetnz.org/topics/basal-cell-carcinoma/\">Basal cell carcinoma</a></td></tr></table>",
        "media": "<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/mmR2R8XB-JU\" data-description=\"Skin cancers\" data-upvotes=\"6\" data-downvotes=\"1\" data-media=\"866\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/mmR2R8XB-JU/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/mmR2R8XB-JU\" data-description=\"Skin cancers\" data-upvotes=\"6\" data-downvotes=\"1\" data-media=\"866\">Skin cancers</a></td></tr><tr><td><span ><small>Osmosis - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1514\" data-mediaid=\"1514\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_1514\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">6</span><button type=\"button\" style=\"\" id=\"media_dislike_1514\" data-mediaid=\"1514\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_1514\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">1</span></td></tr></table>",
        "comment_count": 2,
        "concepts_for_notes": [],
        "optimisation_reason": ""
    },
    {
        "question_id": "495_B_8",
        "new_question_id": "10629",
        "question_type": "0",
        "category": "5",
        "concept_id_link": "0",
        "notes_id_link": "1_856",
        "theme": "",
        "instruction": "",
        "options": [
            "",
            "Thalassemia",
            "B12/folate deficiency",
            "Iron deficiency anaemia",
            "Hypothyroid",
            "Anaemia of chronic disease",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "A 70-year-old gentleman comes to see you to discuss his recent blood tests, which have been done routinely three days ago as part of a health screen. He happens to currently be on day five of antibiotics for a community acquired pneumonia, for which he saw one of your colleagues. Other than this recent infection, he is completely fit and well, with no medical history and no new symptoms to report. <br /><br />His renal function is normal. The remainder of his blood tests are shown below:<br /><br /><div class=\"table-responsive\"><table class = \"tb\" ><tbody><tr><td>Hb</td><td>110 g/l</td></tr><tr><td>Platelets</td><td>540 * 10<sup>9</sup>/l</td></tr><tr><td>WBC</td><td>13 * 10<sup>9</sup>/l</td></tr><tr><td>MCV</td><td>76 * 10<sup>9</sup>/l</td></tr><tr><td>Ferritin</td><td>330 * 10<sup>9</sup>/l</td></tr></tbody></table></div><br />All values were normal one year ago. What is the most likely explanation for his anaemia?",
            "",
            ""
        ],
        "answers": [
            "3",
            "",
            ""
        ],
        "notes": [
            "This gentleman has a microcytic anaemia, most commonly caused by iron deficiency. The history of this gentleman being unwell whilst his bloods were taken is important -ferritin goes up with inflammation, so the fact that it is normal on this blood test may be misleading. He requires further iron studies to test for true iron deficiency.<br /><br />Thalassemia can cause a microcytic anaemia, but his last blood test was normal. Anaemia of chronic disease can cause a microcytic anaemia but is more commonly normocytic and this does not fit with this gentleman's medical history or renal function.<br /><br />B12/folate deficiency and hypothyroid would usually cause a macrocytic anaemia.",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "A 70-year-old gentleman comes to see you to discuss his recent blood tests, which have been done routinely three days ago as part of a health screen. He happens to currently be on day five of antibiotics for a community acquired pneumonia, for which he saw one of your colleagues. Other than this recent infection, he is completely fit and well, with no medical history and no new symptoms to report. <br /><br />His renal function is normal. The remainder of his blood tests are shown below:<br /><br /><div class=\"table-responsive\"><table class = \"tb\" ><tbody><tr><td>Hb</td><td>110 g/l</td></tr><tr><td>Platelets</td><td>540 * 10<sup>9</sup>/l</td></tr><tr><td>WBC</td><td>13 * 10<sup>9</sup>/l</td></tr><tr><td>MCV</td><td>76 * 10<sup>9</sup>/l</td></tr><tr><td>Ferritin</td><td>330 * 10<sup>9</sup>/l</td></tr></tbody></table></div><br />All values were normal one year ago. What is the most likely explanation for his anaemia?",
        "correct_answer": "3",
        "question_notes": "This gentleman has a microcytic anaemia, most commonly caused by iron deficiency. The history of this gentleman being unwell whilst his bloods were taken is important -ferritin goes up with inflammation, so the fact that it is normal on this blood test may be misleading. He requires further iron studies to test for true iron deficiency.<br /><br />Thalassemia can cause a microcytic anaemia, but his last blood test was normal. Anaemia of chronic disease can cause a microcytic anaemia but is more commonly normocytic and this does not fit with this gentleman's medical history or renal function.<br /><br />B12/folate deficiency and hypothyroid would usually cause a macrocytic anaemia.",
        "answer_order": "3",
        "answer": "3",
        "title": "Microcytic anaemia",
        "body": "Causes<br /><ul><li><span class=\"concept\" data-cid=\"9092\">iron-deficiency anaemia</span></li><li><span class=\"concept\" data-cid=\"9093\">thalassaemia</span>*</li><li><span class=\"concept\" data-cid=\"9095\">congenital sideroblastic anaemia</span></li><li>anaemia of chronic disease (more commonly a normocytic, normochromic picture)</li><li><span class=\"concept\" data-cid=\"9096\">lead poisoning</span></li></ul><br />A question sometimes seen in exams gives a history of a normal haemoglobin level associated with a microcytosis. In patients not at risk of thalassaemia, this should raise the possibility of polycythaemia rubra vera which may cause an iron-deficiency secondary to bleeding.<br /><br />New onset microcytic anaemia in elderly patients should be <span class=\"concept\" data-cid=\"9303\">urgently investigated</span> to exclude underlying malignancy.<br /><br />*in <span class=\"concept\" data-cid=\"9094\">beta-thalassaemia</span> minor the microcytosis is often <span class=\"concept\" data-cid=\"5388\">disproportionate</span> to the anaemia",
        "notes_hash": "a1afd9b1bcd12999193cb8ea1fb291fc",
        "knowledge_graph_node_id_link": 10494,
        "concept": "",
        "concept_percentile": 0,
        "concept_colour": "",
        "number_attempts": "6361",
        "up_votes": "130",
        "down_votes": "106",
        "column_array": [
            0,
            "724",
            "376",
            "3243",
            "142",
            "1876",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "",
        "media": "<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/JKlcblPQqrU\" data-description=\"Anemia (Types, Lab Findings, High Yield Images)\" data-upvotes=\"9\" data-downvotes=\"1\" data-media=\"760\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/JKlcblPQqrU/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/JKlcblPQqrU\" data-description=\"Anemia (Types, Lab Findings, High Yield Images)\" data-upvotes=\"9\" data-downvotes=\"1\" data-media=\"760\">Anemia (Types, Lab Findings, High Yield Images)</a></td></tr><tr><td><span ><small>DirtyUSMLE - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1327\" data-mediaid=\"1327\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_1327\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">9</span><button type=\"button\" style=\"\" id=\"media_dislike_1327\" data-mediaid=\"1327\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_1327\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">1</span></td></tr><tr><td>&nbsp;</td></tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/Vh1LZlLCfkU\" data-description=\"Anaemia (anemia) - classification (microcytic, normocytic and macrocytic) and pathophysiology\" data-upvotes=\"4\" data-downvotes=\"5\" data-media=\"816\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/Vh1LZlLCfkU/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/Vh1LZlLCfkU\" data-description=\"Anaemia (anemia) - classification (microcytic, normocytic and macrocytic) and pathophysiology\" data-upvotes=\"4\" data-downvotes=\"5\" data-media=\"816\">Anaemia (anemia) - classification (microcytic, normocytic and macrocytic) and pathophysiology</a></td></tr><tr><td><span ><small>Armando Hasudungan - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_1417\" data-mediaid=\"1417\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_1417\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">4</span><button type=\"button\" style=\"\" id=\"media_dislike_1417\" data-mediaid=\"1417\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_1417\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">5</span></td></tr></table>",
        "comment_count": 9,
        "concepts_for_notes": {
            "9092": {
                "concept_text": "Microcytic - iron-deficiency anaemia",
                "concept_percentile": "34"
            },
            "9094": {
                "concept_text": "Microcytic - beta-thalassaemia",
                "concept_percentile": "44"
            },
            "9095": {
                "concept_text": "Microcytic - congenital sideroblastic anaemia",
                "concept_percentile": "12"
            },
            "9096": {
                "concept_text": "Microcytic - lead poisoning",
                "concept_percentile": "19"
            },
            "9303": {
                "concept_text": "Microcytic anaemia in an elderly patient presenting in primary care should be referred under 2 week wait",
                "concept_percentile": "96"
            }
        },
        "optimisation_reason": ""
    },
    {
        "question_id": "1_B_1746",
        "new_question_id": "6618",
        "question_type": "0",
        "category": "5",
        "concept_id_link": "0",
        "notes_id_link": "1_220",
        "theme": "",
        "instruction": "",
        "options": [
            "",
            "Chronic lymphocytic leukaemia",
            "Myelodysplasia",
            "Myeloma",
            "Acute myeloid leukaemia",
            "Chronic myeloid leukaemia",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "A 50-year-old woman is investigated for weight loss and anaemia. She has no past medical history of note. Clinical examination reveals massive splenomegaly associated with pale conjunctivae. A full blood count is reported as follows:<br /><br /><div class=\"table-responsive\"><table class = \"tb\" ><tbody><tr><td>Hb</td><td>10.9 g/dl</td></tr><tr><td>Platelets</td><td>702 * 10<sup>9</sup>/l</td></tr><tr><td>WCC</td><td>56.6 * 10<sup>9</sup>/l</td></tr><tr><td>Film</td><td>Leucocytosis noted. All stages of granulocyte maturation seen</td></tr></tbody></table></div><br />What is the most likely diagnosis?",
            "",
            ""
        ],
        "answers": [
            "5",
            "",
            ""
        ],
        "notes": [
            "The causes of massive splenomegaly are as follows:<br /><ul><li>myelofibrosis</li><li>chronic myeloid leukaemia</li><li>visceral leishmaniasis (kala-azar)</li><li>malaria</li><li>Gaucher's syndrome</li></ul><br />This narrows the diagnostic possibilities considerably leaving chronic myeloid leukaemia as the most likely diagnosis.<br />",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "A 50-year-old woman is investigated for weight loss and anaemia. She has no past medical history of note. Clinical examination reveals massive splenomegaly associated with pale conjunctivae. A full blood count is reported as follows:<br /><br /><div class=\"table-responsive\"><table class = \"tb\" ><tbody><tr><td>Hb</td><td>10.9 g/dl</td></tr><tr><td>Platelets</td><td>702 * 10<sup>9</sup>/l</td></tr><tr><td>WCC</td><td>56.6 * 10<sup>9</sup>/l</td></tr><tr><td>Film</td><td>Leucocytosis noted. All stages of granulocyte maturation seen</td></tr></tbody></table></div><br />What is the most likely diagnosis?",
        "correct_answer": "5",
        "question_notes": "The causes of massive splenomegaly are as follows:<br /><ul><li>myelofibrosis</li><li>chronic myeloid leukaemia</li><li>visceral leishmaniasis (kala-azar)</li><li>malaria</li><li>Gaucher's syndrome</li></ul><br />This narrows the diagnostic possibilities considerably leaving chronic myeloid leukaemia as the most likely diagnosis.<br />",
        "answer_order": "5",
        "answer": "5",
        "title": "Chronic myeloid leukaemia",
        "body": "The <span class=\"concept\" data-cid=\"9823\">Philadelphia chromosome</span> is present in more than 95% of patients with chronic myeloid leukaemia (CML). It is due to a <span class=\"concept\" data-cid=\"9823\">translocation between the long arm of chromosome 9 and 22 - t(9:22)(q34; q11)</span>. This results in part of the ABL proto-oncogene from chromosome 9 being fused with the BCR gene from chromosome 22. The resulting BCR-ABL gene codes for a fusion protein that has tyrosine kinase activity in excess of normal.<br /><br />Presentation (60-70 years)<br /><ul><li>anaemia: lethargy</li><li>weight loss and sweating are common</li><li><span class=\"concept\" data-cid=\"9315\">splenomegaly</span> may be marked &rarr; abdo discomfort</li><li><span class=\"concept\" data-cid=\"2354\">an increase in granulocytes at different stages of maturation +/- thrombocytosis</span></li><li>decreased leukocyte alkaline phosphatase</li><li>may undergo blast transformation (AML in 80%, ALL in 20%)</li></ul><br />Management<br /><ul><li>imatinib is now considered first-line treatment<ul><li><span class=\"concept\" data-cid=\"533\">inhibitor of the tyrosine kinase</span> associated with the BCR-ABL defect</li><li>very high response rate in chronic phase CML</li></ul></li><li>hydroxyurea</li><li>interferon-alpha</li><li>allogenic bone marrow transplant</li></ul>",
        "notes_hash": "24b21248ff47f566e2b3005573f9765f",
        "knowledge_graph_node_id_link": 1079,
        "concept": "",
        "concept_percentile": 0,
        "concept_colour": "",
        "number_attempts": "5095",
        "up_votes": "55",
        "down_votes": "28",
        "column_array": [
            0,
            "1355",
            "482",
            "80",
            "847",
            "2331",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "",
        "media": "<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/NTTIJR2RRYA\" data-description=\"Chronic leukemia\" data-upvotes=\"13\" data-downvotes=\"3\" data-media=\"386\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/NTTIJR2RRYA/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/NTTIJR2RRYA\" data-description=\"Chronic leukemia\" data-upvotes=\"13\" data-downvotes=\"3\" data-media=\"386\">Chronic leukemia</a></td></tr><tr><td><span ><small>Osmosis - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_664\" data-mediaid=\"664\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_664\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">13</span><button type=\"button\" style=\"\" id=\"media_dislike_664\" data-mediaid=\"664\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_664\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">3</span></td></tr><tr><td>&nbsp;</td></tr><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/ST6mSB-RvE0\" data-description=\"Chronic myeloid leukaemia\" data-upvotes=\"1\" data-downvotes=\"2\" data-media=\"515\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/ST6mSB-RvE0/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/ST6mSB-RvE0\" data-description=\"Chronic myeloid leukaemia\" data-upvotes=\"1\" data-downvotes=\"2\" data-media=\"515\">Chronic myeloid leukaemia</a></td></tr><tr><td><span ><small>Khan Academy - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_895\" data-mediaid=\"895\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_895\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">1</span><button type=\"button\" style=\"\" id=\"media_dislike_895\" data-mediaid=\"895\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_895\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">2</span></td></tr></table>",
        "comment_count": 7,
        "concepts_for_notes": {
            "533": {
                "concept_text": "Chronic myeloid leukaemia - imatinib = tyrosine kinase inhibitor",
                "concept_percentile": "48"
            }
        },
        "optimisation_reason": ""
    },
    {
        "question_id": "999_B_1889",
        "new_question_id": "59834",
        "question_type": "0",
        "category": "1",
        "concept_id_link": "11518",
        "notes_id_link": "1_1178",
        "theme": "ALS management after third shock in VF arrest",
        "instruction": "",
        "options": [
            "",
            "Adrenaline 1mg IV",
            "Amiodarone 300mg IV",
            "Adrenaline 1mg IV followed immediately by amiodarone 300mg IV",
            "Magnesium sulphate 2g IV",
            "Lidocaine 1.5mg/kg IV",
            "",
            "",
            "",
            "",
            ""
        ],
        "num_of_options": 5,
        "questions": [
            "A 58-year-old man collapses in the emergency department. CPR is commenced immediately. The initial rhythm shows ventricular fibrillation. Two shocks have been delivered with 2 minutes of CPR between each shock. The rhythm check after the second period of CPR still shows ventricular fibrillation.<br /><br />What is the most appropriate immediate management following the third shock?",
            "",
            ""
        ],
        "answers": [
            "3",
            "",
            ""
        ],
        "notes": [
            "<b>Adrenaline 1mg IV followed immediately by amiodarone 300mg IV</b> is correct according to the 2021 Resuscitation Council guidelines. After the third shock in VF/pulseless VT, both drugs should be administered during the subsequent CPR cycle. Adrenaline is given first as it has immediate inotropic and vasoconstrictive effects that help maintain coronary and cerebral perfusion pressure during CPR. Amiodarone follows immediately after as an antiarrhythmic to help terminate the VF and prevent its recurrence. The timing is crucial - both drugs are indicated after the third shock, not before it. This combination approach maximises the chances of successful defibrillation in subsequent shocks while maintaining adequate perfusion during ongoing resuscitation efforts.<br /><br /><b>Adrenaline 1mg IV</b> alone would be incomplete management. While adrenaline is indeed indicated after the third shock in VF/pulseless VT, giving it without amiodarone misses the opportunity to provide antiarrhythmic therapy at the appropriate time. The guidelines specifically recommend both drugs after three unsuccessful shocks, as the combination addresses both the haemodynamic support (adrenaline) and rhythm control (amiodarone) aspects of the arrest.<br /><br /><b>Amiodarone 300mg IV</b> alone would also be incomplete. Although amiodarone is correctly indicated after the third shock in refractory VF, omitting adrenaline would fail to provide the essential adrenergic support needed to maintain coronary perfusion pressure during ongoing CPR. The vasoconstrictive effects of adrenaline are crucial for maintaining adequate perfusion to vital organs.<br /><br /><b>Magnesium sulphate 2g IV</b> is not routinely indicated at this stage. Magnesium is considered in specific circumstances such as suspected hypomagnesaemia, torsades de pointes, or in patients on digoxin therapy. In standard VF arrest without these specific indications, magnesium is not part of the immediate management algorithm after the third shock.<br /><br /><b>Lidocaine 1.5mg/kg IV</b> is an alternative antiarrhythmic agent but is only used when amiodarone is unavailable or when a local decision has been made to use lidocaine instead. Since the question doesn't specify amiodarone unavailability, amiodarone remains the first-line antiarrhythmic choice according to current guidelines.",
            "",
            ""
        ],
        "exam_specific_explanation": "",
        "question": "A 58-year-old man collapses in the emergency department. CPR is commenced immediately. The initial rhythm shows ventricular fibrillation. Two shocks have been delivered with 2 minutes of CPR between each shock. The rhythm check after the second period of CPR still shows ventricular fibrillation.<br /><br />What is the most appropriate immediate management following the third shock?",
        "correct_answer": "3",
        "question_notes": "<b>Adrenaline 1mg IV followed immediately by amiodarone 300mg IV</b> is correct according to the 2021 Resuscitation Council guidelines. After the third shock in VF/pulseless VT, both drugs should be administered during the subsequent CPR cycle. Adrenaline is given first as it has immediate inotropic and vasoconstrictive effects that help maintain coronary and cerebral perfusion pressure during CPR. Amiodarone follows immediately after as an antiarrhythmic to help terminate the VF and prevent its recurrence. The timing is crucial - both drugs are indicated after the third shock, not before it. This combination approach maximises the chances of successful defibrillation in subsequent shocks while maintaining adequate perfusion during ongoing resuscitation efforts.<br /><br /><b>Adrenaline 1mg IV</b> alone would be incomplete management. While adrenaline is indeed indicated after the third shock in VF/pulseless VT, giving it without amiodarone misses the opportunity to provide antiarrhythmic therapy at the appropriate time. The guidelines specifically recommend both drugs after three unsuccessful shocks, as the combination addresses both the haemodynamic support (adrenaline) and rhythm control (amiodarone) aspects of the arrest.<br /><br /><b>Amiodarone 300mg IV</b> alone would also be incomplete. Although amiodarone is correctly indicated after the third shock in refractory VF, omitting adrenaline would fail to provide the essential adrenergic support needed to maintain coronary perfusion pressure during ongoing CPR. The vasoconstrictive effects of adrenaline are crucial for maintaining adequate perfusion to vital organs.<br /><br /><b>Magnesium sulphate 2g IV</b> is not routinely indicated at this stage. Magnesium is considered in specific circumstances such as suspected hypomagnesaemia, torsades de pointes, or in patients on digoxin therapy. In standard VF arrest without these specific indications, magnesium is not part of the immediate management algorithm after the third shock.<br /><br /><b>Lidocaine 1.5mg/kg IV</b> is an alternative antiarrhythmic agent but is only used when amiodarone is unavailable or when a local decision has been made to use lidocaine instead. Since the question doesn't specify amiodarone unavailability, amiodarone remains the first-line antiarrhythmic choice according to current guidelines.",
        "answer_order": "3",
        "answer": "3",
        "title": "Adult advanced life support",
        "body": "The following is based on the 2021 Resus Council guidelines. Please see the link for more details, below is only a very brief summary of key points.<br /><br />It should be remembered that the algorithm divides patients into those with:<br /><ul><li>'shockable' rhythms:  ventricular fibrillation/pulseless ventricular tachycardia (VF/pulseless VT)</li><li>'non-shockable' rhythms: asystole/pulseless-electrical activity (asystole/PEA)</li></ul><br />Major points include:<br /><ul><li>chest compressions<ul><li>the ratio of chest compressions to ventilation is <span class=\"concept\" data-cid=\"11516\">30:2</span></li><li>chest compressions are now continued while a defibrillator is charged</li></ul></li><li>defibrillation<ul><li><span class=\"concept\" data-cid=\"9130\">a single shock for VF/pulseless VT</span> followed by 2 minutes of CPR</li></ul></li><li>drug delivery<ul><li>IV access should be attempted and is first-line</li><li>if IV access cannot be achieved then drugs should be given via the <span class=\"concept\" data-cid=\"11515\">intraosseous route (IO)</span></li><li>delivery of drugs via a <span class=\"concept\" data-cid=\"11515\">tracheal tube is no longer recommended</span></li></ul></li><li>adrenaline<ul><li><span class=\"concept\" data-cid=\"8608\">adrenaline 1 mg as soon as possible for non-shockable rhythms</span></li><li>during a VF/VT cardiac arrest, <span class=\"concept\" data-cid=\"9925\">adrenaline 1 mg</span> is given once chest compressions have restarted after the third shock </li><li><span class=\"concept\" data-cid=\"11517\">repeat adrenaline 1mg every 3-5 minutes</span> whilst ALS continues</li></ul></li><li>amiodarone<ul><li><span class=\"concept\" data-cid=\"11518\">amiodarone 300 mg should be given to patients who are in VF/pulseless VT after 3 shocks</span> have been administered.</li><li><span class=\"concept\" data-cid=\"11519\">a further dose of amiodarone 150 mg should be given to patients who are in VF/pulseless VT after 5 shocks</span> have been administered</li><li><span class=\"concept\" data-cid=\"11520\">lidocaine</span> used as an alternative if amiodarone is not available or a local decision has been made to use lidocaine instead</li></ul></li><li><span class=\"concept\" data-cid=\"11521\">thrombolytic drugs</span><ul><li>should be considered if a pulmonary embolus  is suspected</li><li>if given, CPR should be continued for an extended period of <span class=\"concept\" data-cid=\"11522\">60-90 minutes</span></li></ul></li></ul><br /><div class=\"container\"><div class=\"row\"><div class=\"col-md-3\"><a href=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd964b.png\" data-fancybox=\"gallery\" data-caption=\"\"><img  class=\"img-thumbnail mx-auto d-block\" style=\"max-height:150px;margin-bottom:10px;\" src=\"https://d32xxyeh8kfs8k.cloudfront.net/images_Passmedicine/pdd964.png\" alt=\"\" /></a></div></div></div><br />Other points<br /><ul><li><span class=\"concept\" data-cid=\"198\">atropine</span> is no longer recommended for routine use in asystole or pulseless electrical activity (PEA)</li><li>following successful resuscitation oxygen should be titrated to achieve saturations of 94-98%. This is to address the potential harm caused by hyperoxaemia</li></ul><br />Reversible causes of cardiac arrest:<br /><br /><div class=\"table-responsive\"><table class = \"tlarge table table-striped table-bordered\"  data-role=\"table\" id=\"tableid1\" ><thead><tr><th>The 'Hs'</th><th>The 'Ts'</th></tr></thead><tbody><tr><td><ul><li>Hypoxia</li><li>Hypovolaemia</li><li>Hyperkalaemia, hypokalaemia, hypoglycaemia, hypocalcaemia, acidaemia and other metabolic disorders</li><li>Hypothermia</td><td></li><li>Thrombosis (coronary or pulmonary)</li><li><span class=\"concept\" data-cid=\"5831\">Tension pneumothorax</span></li><li>Tamponade - cardiac</li><li>Toxins</td></tr></tbody></table></div></li></ul>",
        "notes_hash": "01cd06e39a409427e046421edca879c8",
        "knowledge_graph_node_id_link": 11290,
        "concept": "In ALS, amiodarone 300 mg should be given to patients who are in VF/pulseless VT after 3 shocks have been administered.",
        "concept_percentile": "44",
        "concept_colour": "rgb(255,224,0)",
        "number_attempts": "2874",
        "up_votes": "1",
        "down_votes": "3",
        "column_array": [
            0,
            "686",
            "740",
            "1416",
            "29",
            "3",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0",
            "0"
        ],
        "links": "<table style='width:100%'><tr><td>Resuscitation Council</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_1018\" data-linkid=\"1018\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_1018\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">67</span><button type=\"button\" style=\"\" id=\"link_dislike_1018\" data-linkid=\"1018\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_1018\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">35</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https://www.resus.org.uk/library/2021-resuscitation-guidelines/adult-advanced-life-support-guidelines\">2021 Advanced Life Support guidelines</a></td></tr></table><br><br><table style='width:100%'><tr><td>Resuscitation Council</td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"link_like_906\" data-linkid=\"906\" data-rating=\"1\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"link_good_count_906\" class = \"link_good_count\" style=\"color:green; font-size:85%;\">42</span><button type=\"button\" style=\"\" id=\"link_dislike_906\" data-linkid=\"906\" data-rating=\"0\" class=\"rate-link btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"link_bad_count_906\" class = \"link_bad_count\" style=\"color:red; font-size:85%;\">22</span></td></tr><tr><td colspan=\"2\"><a target=\"_blank\" href=\"https://www.resus.org.uk/library/2021-resuscitation-guidelines/adult-basic-life-support-guidelines\">2021 Basic Life Support guidelines</a></td></tr></table>",
        "media": "<table><tr><td colspan=\"2\"><a href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/jQYHQr3ebLo\" data-description=\"RC (UK) Cardiac Arrest Management Demo\" data-upvotes=\"51\" data-downvotes=\"5\" data-media=\"1181\"><img border=\"0\" class=\"img-thumbnail\" alt=\"YouTube\" src=\"https://i1.ytimg.com/vi/jQYHQr3ebLo/mqdefault.jpg\" style=\"max-width:150px;\"></a></td></tr><tr ><td style=\"padding-top:10px\" colspan=\"2\"><a style=\"\" href=\"#\" class=\"media_link\" data-url=\"https://www.youtube.com/embed/jQYHQr3ebLo\" data-description=\"RC (UK) Cardiac Arrest Management Demo\" data-upvotes=\"51\" data-downvotes=\"5\" data-media=\"1181\">RC (UK) Cardiac Arrest Management Demo</a></td></tr><tr><td><span ><small>Resuscitation Council (UK) - YouTube</small></span></td><td style = \"float: right;width:115px;\"><button type=\"button\" style=\"\" id=\"media_like_2037\" data-mediaid=\"2037\" data-rating=\"1\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-up\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-up\"/></svg></button><span id=\"media_good_count_2037\" class = \"media_good_count\" style=\"color:green; font-size:85%;\">51</span><button type=\"button\" style=\"\" id=\"media_dislike_2037\" data-mediaid=\"2037\" data-rating=\"0\" class=\"rate-media btn btn-link\"><svg class=\"bi bi-hand-thumbs-down\" width=\"16\" height=\"16\"><use xlink:href=\"#icon-hand-thumbs-down\"/></svg></button><span id=\"media_bad_count_2037\" class = \"media_bad_count\" style=\"color:red; font-size:85%;\">5</span></td></tr></table>",
        "comment_count": 1,
        "concepts_for_notes": {
            "8608": {
                "concept_text": "ALS - give adrenaline in non-shockable rhythm as soon as possible",
                "concept_percentile": "72"
            },
            "9130": {
                "concept_text": "VF/pulseless VT should be treated with 1 shock as soon as identified",
                "concept_percentile": "41"
            },
            "9925": {
                "concept_text": "The recommended dose of adrenaline to give during advanced ALS is 1mg",
                "concept_percentile": "42"
            },
            "11515": {
                "concept_text": "In ALS, if IV access cannot be achieved then drugs should be given via the intraosseous route (IO) - the tracheal route is no longer recommended",
                "concept_percentile": "30"
            },
            "11516": {
                "concept_text": "In ALS, the ratio of chest compressions to ventilation is 30:2",
                "concept_percentile": "28"
            },
            "11517": {
                "concept_text": "In ALS, once adrenaline has been initially given it should be repeated every 3-5 minutes whilst ALS continues",
                "concept_percentile": "53"
            },
            "11518": {
                "concept_text": "In ALS, amiodarone 300 mg should be given to patients who are in VF/pulseless VT after 3 shocks have been administered.",
                "concept_percentile": "44"
            },
            "11519": {
                "concept_text": "In ALS, a further dose of amiodarone 150 mg should be given to patients who are in VF/pulseless VT after 5 shocks have been administered",
                "concept_percentile": "48"
            },
            "11521": {
                "concept_text": "Thrombolytic drugs should be considered during CPR if a PE is suspected",
                "concept_percentile": "71"
            }
        },
        "optimisation_reason": ""
    }
]